{"id":"NCT03303105","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine","officialTitle":"A Multicenter, Randomized, Open-label Trial Evaluating the Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-07","primaryCompletion":"2020-06-16","completion":"2020-06-16","firstPosted":"2017-10-05","resultsPosted":"2021-07-16","lastUpdate":"2023-02-17"},"enrollment":50,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"TEV-48125","otherNames":[]},{"type":"DRUG","name":"TEV-48125","otherNames":[]}],"arms":[{"label":"TEV-48125 (225 mg/1 month) group","type":"EXPERIMENTAL"},{"label":"TEV-48125 (675 mg/3 month) group","type":"EXPERIMENTAL"}],"summary":"To evaluate the long-term safety and tolerability of subcutaneous (SC) administration of TEV-48125 (at 225 mg once monthly \\[except for a loading dose of 675 mg for CM patients\\] or at 675 mg every 3 months) for the preventive treatment of Chronic Migraine and Episodic Migraine patients","primaryOutcome":{"measure":"Percentage of Subjects With at Least One Treatment-Emergent Adverse Event (TEAE)","timeFrame":"Baseline (Day 0) up to follow-up visit (Day 562)","effectByArm":[{"arm":"TEV-48125 (225 mg/1 Month) Group","deltaMin":92,"sd":null},{"arm":"TEV-48125 (675 mg/3 Month) Group","deltaMin":88,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["34687446"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Nasopharyngitis","Injection site erythema","Injection site induration","Injection site pain","Gastroenteritis"]}}